Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from Guggenheim

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a report released on Friday,Benzinga reports. They currently have a $60.00 price objective on the stock. Guggenheim’s target price points to a potential upside of 50.00% from the stock’s previous close.

A number of other research analysts have also weighed in on the stock. BTIG Research lifted their price objective on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Wedbush increased their target price on Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. UBS Group began coverage on Oruka Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. Jefferies Financial Group started coverage on Oruka Therapeutics in a research report on Thursday, November 13th. They issued a “buy” rating and a $45.00 price target for the company. Finally, Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $56.67.

Oruka Therapeutics Stock Up 25.0%

Shares of NASDAQ:ORKA opened at $40.00 on Friday. The firm has a market capitalization of $1.94 billion, a PE ratio of -21.51 and a beta of -0.38. The company has a 50-day moving average price of $32.92 and a two-hundred day moving average price of $27.59. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $41.19.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. Analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the transaction, the insider owned 34,018 shares of the company’s stock, valued at approximately $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 21,000 shares of company stock worth $663,530 over the last three months. 24.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ORKA. Royal Bank of Canada grew its position in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares in the last quarter. Kennedy Capital Management LLC raised its position in shares of Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after buying an additional 420 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after buying an additional 788 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Oruka Therapeutics by 62.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after buying an additional 904 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics during the fourth quarter worth about $37,000. 56.44% of the stock is owned by institutional investors.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.